Novozymes (NVZMY)
(Delayed Data from OTC)
$63.74 USD
-0.11 (-0.17%)
Updated Aug 14, 2024 03:59 PM ET
2-Buy of 5 2
F Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Novozymes AS falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 162 | 147 | 153 | 181 | 107 |
Receivables | 621 | 590 | 597 | 493 | 511 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 527 | 539 | 476 | 362 | 392 |
Other Current Assets | 64 | 33 | 18 | 23 | 48 |
Total Current Assets | 1,374 | 1,309 | 1,245 | 1,059 | 1,057 |
Net Property & Equipment | 1,790 | 1,710 | 1,620 | 1,473 | 1,531 |
Investments & Advances | 30 | 32 | 5 | 5 | 6 |
Other Non-Current Assets | 6 | 5 | 6 | 6 | 4 |
Deferred Charges | 256 | 230 | 260 | 205 | 174 |
Intangibles | 658 | 665 | 799 | 391 | 289 |
Deposits & Other Assets | 9 | 13 | 5 | 3 | 3 |
Total Assets | 4,122 | 3,962 | 3,940 | 3,142 | 3,064 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 235 | 265 | 237 | 169 | 167 |
Current Portion Long-Term Debt | 448 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 27 | 46 | 77 | 51 | 65 |
Other Current Liabilities | 326 | 658 | 569 | 397 | 453 |
Total Current Liabilities | 1,054 | 986 | 903 | 637 | 710 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 285 | 252 | 228 | 184 | 132 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 629 | 512 | 585 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 37 | 156 | 225 | 539 | 433 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,039 | 1,948 | 1,998 | 1,420 | 1,343 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 82 | 80 | 90 | 87 | 87 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 1,997 | 1,850 | 0 | 1,725 | 1,620 |
Other Equity | 5 | 86 | 1,852 | -90 | 13 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,084 | 2,015 | 1,942 | 1,723 | 1,721 |
Total Liabilities & Shareholder's Equity | 4,122 | 3,962 | 3,940 | 3,142 | 3,064 |
Total Common Equity | 2,084 | 2,015 | 1,942 | 1,723 | 1,721 |
Shares Outstanding | 468.30 | 227.20 | 228.20 | 297.00 | 297.00 |
Book Value Per Share | 4.45 | 8.87 | 8.51 | 5.80 | 5.79 |
Fiscal Year End for Novozymes AS falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 162 | 172 | 153 |
Receivables | NA | NA | 621 | 622 | 611 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 527 | 566 | 579 |
Other Current Assets | NA | NA | 64 | 18 | 27 |
Total Current Assets | NA | NA | 1,374 | 1,378 | 1,370 |
Net Property & Equipment | NA | NA | 1,790 | 1,851 | 1,802 |
Investments & Advances | NA | NA | 30 | 31 | 32 |
Other Non-Current Assets | NA | NA | 6 | 5 | 4 |
Deferred Charges | NA | NA | 256 | 222 | 236 |
Intangibles | NA | NA | 658 | 666 | 667 |
Deposits & Other Assets | NA | NA | 9 | 13 | 13 |
Total Assets | NA | NA | 4,122 | 4,167 | 4,124 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | NA | 235 | 213 | 193 |
Current Portion Long-Term Debt | NA | NA | 448 | 344 | 461 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 0 | 0 | 0 |
Income Taxes Payable | NA | NA | 27 | 75 | 55 |
Other Current Liabilities | NA | NA | 326 | 259 | 271 |
Total Current Liabilities | NA | NA | 1,054 | 909 | 999 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 285 | 263 | 269 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 629 | 646 | 668 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 37 | 138 | 133 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 2,039 | 1,993 | 2,108 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 82 | 82 | 82 |
Capital Surplus | NA | NA | 0 | 0 | 0 |
Retained Earnings | NA | NA | 1,997 | 2,017 | 1,885 |
Other Equity | NA | NA | 5 | 75 | 49 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | 2,084 | 2,174 | 2,016 |
Total Liabilities & Shareholder's Equity | NA | NA | 4,122 | 4,167 | 4,124 |
Total Common Equity | 0 | 0 | 2,084 | 2,174 | 2,016 |
Shares Outstanding | 468.30 | 468.30 | 468.30 | 227.20 | 227.20 |
Book Value Per Share | 0.00 | 0.00 | 4.45 | 9.57 | 8.87 |